サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：急性リンパ性白血病の世界市場 (2022年～2031年)：産業分析・規模・シェア・成長・動向・予測
市場調査レポート
商品コード
1166057

急性リンパ性白血病の世界市場 (2022年～2031年)：産業分析・規模・シェア・成長・動向・予測

Acute Lymphoblastic Leukemia Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 192 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
急性リンパ性白血病の世界市場 (2022年～2031年)：産業分析・規模・シェア・成長・動向・予測
出版日: 2022年10月28日
発行: Transparency Market Research
ページ情報: 英文 192 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の急性リンパ性白血病の市場を調査し、市場概要、市場成長への各種影響因子の分析、パイプライン分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 序文

第2章 前提と調査手法

第3章 エグゼクティブサマリー：世界の急性リンパ性白血病市場

第4章 市場概要

  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • 世界の急性リンパ性白血病市場の分析・予測

第5章 主な洞察

  • 世界の疾病有病率・発生率
  • 主要な産業イベント（M&A・提携など）
  • パイプライン分析
  • COVID-19の産業への影響（バリューチェーンと短期・中期・長期の影響）

第6章 世界の急性リンパ性白血病市場の分析・予測：タイプ別

  • イントロダクション・定義
  • 主な調査結果/展開
  • 市場規模・予測
    • B細胞性急性リンパ性白血病
    • T細胞リンパ性白血病
  • 市場の魅力

第7章 世界の急性リンパ性白血病市場の分析・予測：治療別

  • イントロダクション・定義
  • 主な調査結果/展開
  • 市場規模・予測
    • 化学療法
    • 放射線療法
    • 骨髄移植
    • 標的療法
    • 免疫療法
  • 市場の魅力

第8章 世界の急性リンパ性白血病市場の分析・予測：エンドユーザー別

  • イントロダクション・定義
  • 主な調査結果/展開
  • 市場規模・予測
    • 病院
    • 診療所
    • その他
  • 市場の魅力

第9章 世界の急性リンパ性白血病市場の分析・予測：地域別

  • 主な調査結果
  • 市場規模・予測
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力

第10章 北米の急性リンパ性白血病市場の分析・予測

第11章 欧州の急性リンパ性白血病市場の分析・予測

第12章 アジア太平洋の急性リンパ性白血病市場の分析・予測

第13章 ラテンアメリカの急性リンパ性白血病市場の分析・予測

第14章 中東・アフリカの急性リンパ性白血病市場の分析・予測

第15章 競合情勢

  • 参入企業・競合マトリックス
  • 市場シェア分析：企業別
  • 企業プロファイル
    • Amgen, Inc.
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Erytech Pharma, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Kite Pharma, Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Sanofi
    • Spectrum Pharmaceuticals, Inc.
図表

List of Tables

  • Table 01: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Type, 2017-2031
  • Table 02: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Treatment, 2017-2031
  • Table 03: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by End-user, 2017-2031
  • Table 04: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Region, 2017-2031
  • Table 05: North America Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Country, 2017-2031
  • Table 06: North America Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Type, 2017-2031
  • Table 07: North America Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Treatment, 2017-2031
  • Table 08: North America Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by End-user, 2017-2031
  • Table 09: Europe Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Type, 2017-2031
  • Table 11: Europe Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Treatment, 2017-2031
  • Table 12: Europe Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by End-user, 2017-2031
  • Table 13: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Type, 2017-2031
  • Table 15: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Treatment, 2017-2031
  • Table 16: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by End-user, 2017-2031
  • Table 17: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Type, 2017-2031
  • Table 19: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Treatment, 2017-2031
  • Table 20: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by End-user, 2017-2031
  • Table 21: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Type, 2017-2031
  • Table 23: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Treatment, 2017-2031
  • Table 24: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, 2017-2031
  • Figure 02: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Type, 2021
  • Figure 03: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2021
  • Figure 04: Global Acute Lymphoblastic Leukemia Market Value Share (%), by End-user, 2021
  • Figure 05: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Region, 2021
  • Figure 06: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Type, 2021 and 2031
  • Figure 07: Global Acute Lymphoblastic Leukemia Market Attractiveness, by Type, 2022-2031
  • Figure 08: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by B-cell, 2017-2031
  • Figure 09: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by T-cell, 2017-2031
  • Figure 10: Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment, 2022-2031
  • Figure 11: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by Chemotherapy, 2017-2031
  • Figure 12: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by Radiation Therapy, 2017-2031
  • Figure 13: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by Bone Marrow Transplant, 2017-2031
  • Figure 14: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by Targeted Therapy, 2017-2031
  • Figure 15: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by Immunotherapy, 2017-2031
  • Figure 16: Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Treatment, 2022-2031
  • Figure 17: Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 18: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by Hospitals, 2017-2031
  • Figure 19: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by Clinics, 2017-2031
  • Figure 20: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by Others, 2017-2031
  • Figure 21: Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 22: Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 23: Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 24: North America Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 25: North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 26: North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 27: North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 28: North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 29: North America Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2021 and 2031
  • Figure 30: North America Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2022-2031
  • Figure 31: North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 32: North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 33: Europe Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 34: Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 35: Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 36: Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 37: Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 38: Europe Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2021 and 2031
  • Figure 39: Europe Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2022-2031
  • Figure 40: Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 41: Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 42: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 43: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 44: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 45: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 46: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 47: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2021 and 2031
  • Figure 48: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2022-2031
  • Figure 49: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 50: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 51: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 52: Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 53: Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 54: Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 55: Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 56: Latin America Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2021 and 2031
  • Figure 57: Latin America Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2022-2031
  • Figure 58: Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 59: Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 60: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, 2017-2031
  • Figure 61: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 62: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 63: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 64: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 65: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2021 and 2031
  • Figure 66: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2022-2031
  • Figure 67: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 68: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 69: Global Acute Lymphoblastic Leukemia Market Share, by Company, 2021
目次
Product Code: TMRGL22886

TMR's report on the global acute lymphoblastic leukemia market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global acute lymphoblastic leukemia market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global acute lymphoblastic leukemia market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the acute lymphoblastic leukemia market.

The report delves into the competitive landscape of the global acute lymphoblastic leukemia market. Key players operating in the global acute lymphoblastic leukemia market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global acute lymphoblastic leukemia market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Acute Lymphoblastic Leukemia Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

  • 5.1. Disease Prevalence & Incidence Rate globally
  • 5.2. Key Industry Events (mergers, acquisitions, partnerships, etc.)
  • 5.3. Pipeline Analysis
  • 5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Type, 2017-2031
    • 6.3.1. B-cell Acute Lymphoblastic Leukemia
    • 6.3.2. T-cell Lymphoblastic Leukemia
  • 6.4. Market Attractiveness Analysis, by Type

7. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, by Treatment

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Treatment, 2017-2031
    • 7.3.1. Chemotherapy
    • 7.3.2. Radiation Therapy
    • 7.3.3. Bone Marrow Transplant
    • 7.3.4. Targeted Therapy
    • 7.3.5. Immunotherapy
  • 7.4. Market Attractiveness Analysis, by Treatment

8. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by End-user, 2017-2031
    • 8.3.1. Hospitals
    • 8.3.2. Clinics
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis, by End-user

9. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Acute Lymphoblastic Leukemia Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Type, 2017-2031
    • 10.2.1. B-cell Acute Lymphoblastic Leukemia
    • 10.2.2. T-cell Lymphoblastic Leukemia
  • 10.3. Market Value Forecast, by Treatment, 2017-2031
    • 10.3.1. Chemotherapy
    • 10.3.2. Radiation Therapy
    • 10.3.3. Bone Marrow Transplant
    • 10.3.4. Targeted Therapy
    • 10.3.5. Immunotherapy
  • 10.4. Market Value Forecast, by End-user, 2017-2031
    • 10.4.1. Hospitals
    • 10.4.2. Clinics
    • 10.4.3. Others
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Type
    • 10.6.2. By Treatment
    • 10.6.3. By End-user
    • 10.6.4. By Country

11. Europe Acute Lymphoblastic Leukemia Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Type, 2017-2031
    • 11.2.1. B-cell Acute Lymphoblastic Leukemia
    • 11.2.2. T-cell Lymphoblastic Leukemia
  • 11.3. Market Value Forecast, by Treatment, 2017-2031
    • 11.3.1. Chemotherapy
    • 11.3.2. Radiation Therapy
    • 11.3.3. Bone Marrow Transplant
    • 11.3.4. Targeted Therapy
    • 11.3.5. Immunotherapy
  • 11.4. Market Value Forecast, by End-user, 2017-2031
    • 11.4.1. Hospitals
    • 11.4.2. Clinics
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Type
    • 11.6.2. By Treatment
    • 11.6.3. By End-user
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Acute Lymphoblastic Leukemia Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Type, 2017-2031
    • 12.2.1. B-cell Acute Lymphoblastic Leukemia
    • 12.2.2. T-cell Lymphoblastic Leukemia
  • 12.3. Market Value Forecast, by Treatment, 2017-2031
    • 12.3.1. Chemotherapy
    • 12.3.2. Radiation Therapy
    • 12.3.3. Bone Marrow Transplant
    • 12.3.4. Targeted Therapy
    • 12.3.5. Immunotherapy
  • 12.4. Market Value Forecast, by End-user, 2017-2031
    • 12.4.1. Hospitals
    • 12.4.2. Clinics
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Type
    • 12.6.2. By Treatment
    • 12.6.3. By End-user
    • 12.6.4. By Country/Sub-region

13. Latin America Acute Lymphoblastic Leukemia Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Type, 2017-2031
    • 13.2.1. B-cell Acute Lymphoblastic Leukemia
    • 13.2.2. T-cell Lymphoblastic Leukemia
  • 13.3. Market Value Forecast, by Treatment, 2017-2031
    • 13.3.1. Chemotherapy
    • 13.3.2. Radiation Therapy
    • 13.3.3. Bone Marrow Transplant
    • 13.3.4. Targeted Therapy
    • 13.3.5. Immunotherapy
  • 13.4. Market Value Forecast, by End-user, 2017-2031
    • 13.4.1. Hospitals
    • 13.4.2. Clinics
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Type
    • 13.6.2. By Treatment
    • 13.6.3. By End-user
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Acute Lymphoblastic Leukemia Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Type, 2017-2031
    • 14.2.1. B-cell Acute Lymphoblastic Leukemia
    • 14.2.2. T-cell Lymphoblastic Leukemia
  • 14.3. Market Value Forecast, by Treatment, 2017-2031
    • 14.3.1. Chemotherapy
    • 14.3.2. Radiation Therapy
    • 14.3.3. Bone Marrow Transplant
    • 14.3.4. Targeted Therapy
    • 14.3.5. Immunotherapy
  • 14.4. Market Value Forecast, by End-user, 2017-2031
    • 14.4.1. Hospitals
    • 14.4.2. Clinics
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Type
    • 14.6.2. By Treatment
    • 14.6.3. By End-user
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. Amgen, Inc.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Company Financials
      • 15.3.1.3. Growth Strategies
      • 15.3.1.4. SWOT Analysis
    • 15.3.2. Bristol-Myers Squibb Company
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Company Financials
      • 15.3.2.3. Growth Strategies
      • 15.3.2.4. SWOT Analysis
    • 15.3.3. Celgene Corporation
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Company Financials
      • 15.3.3.3. Growth Strategies
      • 15.3.3.4. SWOT Analysis
    • 15.3.4. Erytech Pharma, Inc.
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Company Financials
      • 15.3.4.3. Growth Strategies
      • 15.3.4.4. SWOT Analysis
    • 15.3.5. F. Hoffmann-La Roche Ltd.
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Company Financials
      • 15.3.5.3. Growth Strategies
      • 15.3.5.4. SWOT Analysis
    • 15.3.6. Kite Pharma, Inc.
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Company Financials
      • 15.3.6.3. Growth Strategies
      • 15.3.6.4. SWOT Analysis
    • 15.3.7. Novartis AG
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Company Financials
      • 15.3.7.3. Growth Strategies
      • 15.3.7.4. SWOT Analysis
    • 15.3.8. Pfizer, Inc.
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Company Financials
      • 15.3.8.3. Growth Strategies
      • 15.3.8.4. SWOT Analysis
    • 15.3.9. Sanofi
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Company Financials
      • 15.3.9.3. Growth Strategies
      • 15.3.9.4. SWOT Analysis
    • 15.3.10. Spectrum Pharmaceuticals, Inc.
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Company Financials
      • 15.3.10.3. Growth Strategies
      • 15.3.10.4. SWOT Analysis